Vis enkel innførsel

dc.contributor.authorRokstad, Anne Mari
dc.contributor.authorStrand, Berit Løkensgard
dc.contributor.authorEspevik, Terje
dc.contributor.authorMollnes, Tom Eirik
dc.date.accessioned2017-10-26T13:36:03Z
dc.date.available2017-10-26T13:36:03Z
dc.date.created2014-01-16T08:26:37Z
dc.date.issued2013
dc.identifier.citationMicro and Nanosystems. 2013, 5 (3), 177-185.nb_NO
dc.identifier.issn1876-4029
dc.identifier.urihttp://hdl.handle.net/11250/2462413
dc.description.abstractThe whole blood model is a powerful method to determine the immediate inflammatory reactions towards foreign objects in general. This review focuses on the use of a lepirudin based whole blood model for evaluating microspheres relevant in cell transplantation applications. This whole blood model can be regarded as a holistic model with readouts from cross-talks between leukocytes, complement, most of the coagulation components and fibrinolysis. A major advantage of this model is the possibility of evaluating a panel of different microspheres under identical conditions, and also the possibility of comparing reaction patterns between species. This model is a valuable tool for gaining a mechanistic understanding by selected readouts (as complement and coagulation activation products, cytokines, cell-surface receptors, protein adsorption, cell-attachment), and by use of inflammatory blocking agents (inhibitors). The whole blood model is put in the context of today’s knowledge about inflammatory systems, discussed according to biocompatibility and biotolerability terms and finally discussed according to its ability to predict the outcome of transplanted microspheres in an in vivo environment.nb_NO
dc.language.isoengnb_NO
dc.publisherBentham Science Publishersnb_NO
dc.titleBiocompatibility and Biotolerability Assessment of Microspheres Using a Whole Blood Modelnb_NO
dc.typeJournal articlenb_NO
dc.description.versionsubmittedVersionnb_NO
dc.source.pagenumber177-185nb_NO
dc.source.volume5nb_NO
dc.source.journalMicro and Nanosystemsnb_NO
dc.source.issue3nb_NO
dc.identifier.doi10.2174/1876402911305030005
dc.identifier.cristin1091465
dc.relation.projectNorges forskningsråd: 223255nb_NO
dc.relation.projectSamarbeidsorganet mellom Helse Midt-Norge og NTNU: 46049600nb_NO
dc.description.localcodeThis is a submitted manuscript of an article available at EurekaSelect via http://www.eurekaselect.com/112574/articlenb_NO
cristin.unitcode194,65,15,0
cristin.unitcode194,66,15,0
cristin.unitcode194,65,15,30
cristin.unitnameInstitutt for kreftforskning og molekylær medisin
cristin.unitnameInstitutt for bioteknologi
cristin.unitnameCentre of Molecular Inflammation Research (SFF-CEMIR)
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel